Posted by Michael Wonder on 03 Mar 2022
AltPep receives FDA breakthrough device designation for SOBA-AD, a simple blood test for the detection of Alzheimer’s disease
1 March 2022 - AltPep Corporation today announced the U.S. FDA granted the company breakthrough device designation for its SOBA-AD diagnostic in development for Alzheimer’s disease.
The long-term potential for the SOBA-AD assay lies in its ability to detect disease early, even before symptoms arise. Early detection may lead to more effective treatments that limit cognitive decline in Alzheimer's disease patients.
